Welcome to our dedicated page for Vaso news (Ticker: VASO), a resource for investors and traders seeking the latest updates and insights on Vaso stock.
Vaso Corporation (OTCQX: VASO) generates a steady flow of news related to its activities in medical technology, healthcare IT, and professional sales services. The company describes itself as a diversified MedTech and information technology business with operations in managed IT systems and services, healthcare professional sales services, and proprietary medical devices, and its announcements reflect developments across these areas.
News items frequently cover quarterly and annual financial results, where Vaso reports revenue, gross profit, segment performance, and the use of non-GAAP measures such as Adjusted EBITDA. These releases often highlight contributions from its IT, professional sales service, and equipment segments, as well as trends in deferred revenue and subscription revenues.
Another key category of updates involves commercial partnerships and long-term agreements. For example, the company has announced multiple extensions of the sales representation agreement between its VasoHealthcare subsidiary and GE HealthCare. A December 2025 release described the fifth extension of this agreement, which continues VasoHealthcare’s exclusive sales representation of GE HealthCare diagnostic imaging and ultrasound products in certain U.S. market segments through December 31, 2030.
Vaso’s news flow also includes strategic transactions and corporate actions. In November 2025, the company announced an agreement, subject to certain conditions, to sell its VasoHealthcare IT Corp. subsidiary to Nano-X Imaging Ltd., following a strategic review of its lines of business. Other releases address executive leadership appointments, board roles, and shareholder communications such as CEO letters summarizing achievements and strategic priorities.
Investors and observers who follow VASO news can expect coverage of financial performance, segment updates, long-term sales agreements, divestitures, leadership changes, and shareholder meeting information, providing insight into how the company manages its diversified MedTech and IT portfolio.
Vaso Corporation (OTCQX: VASO) announced that its subsidiary VasoHealthcare signed an amendment extending its sales representation agreement with GE HealthCare (NASDAQ: GEHC) through December 31, 2030. This marks the fifth extension of a partnership that began in May 2010, which will span over 20 years under the latest term.
Under the amendment, VasoHealthcare will continue representing GE HealthCare’s diagnostic imaging and ultrasound portfolio, including CT, MR, molecular imaging, X-ray, mammography, interventional solutions, plus related service and financial offerings, aiming to ensure continuity in sales representation and customer support nationwide.
Vaso Corporation (OTCQX: VASO) announced on November 19, 2025 that it reached an agreement, subject to conditions, to sell its subsidiary VasoHealthcare IT Corp. to Nano-X Imaging (Nasdaq: NNOX).
The buyer will pay up to $800,000 in total consideration: $200,000 at closing and up to $600,000 as an earnout tied to post-closing performance. VasoHealthcare IT represented less than 5% of Vaso’s total revenue. The parties intend to complete the sale within a couple of weeks. Vaso said it expects to use proceeds to invest in other business lines and strategic initiatives.
Vaso (OTCQX: VASO) reported third-quarter 2025 results for the three months ended September 30, 2025, with total revenue of $22.7 million, up 9.1% year‑over‑year. Gross profit rose to $13.9 million, an increase of 18.2%, and the company recorded net income of $1.7 million versus a net loss of $1.2 million in Q3 2024, a $2.9 million improvement. Adjusted EBITDA was $1.6 million versus negative $1.2 million a year earlier. Cash and cash equivalents were $34.9 million at quarter end, and operating cash flow for the first nine months of 2025 was $9.0 million versus $3.6 million in the prior-year period.
All three business segments contributed to revenue growth; professional sales services led with an 18.7% increase. SG&A rose modestly while deferred and subscription revenues continued to trend upward.
Vaso Corporation (OTCQX: VASO), a MedTech company, reported its Q2 2025 financial results with revenue of $20.0 million, slightly down 1.3% from $20.2 million in Q2 2024. The company posted a net loss of $197,000 compared to a net income of $1.2 million in the same period last year.
The company's professional sales service segment experienced a 4.0% decline, while the IT segment saw a 0.9% increase. Notable metrics include record-high deferred revenue of $38.1 million (up from $31.7 million YoY), gross profit of $11.8 million (down 2.9%), and strong cash position of $32.6 million. Operating cash flow for Q2 2025 was $6.8 million, demonstrating robust cash generation despite operational challenges.
The professional sales service segment saw a 7.1% revenue increase, while the IT segment grew by 1.6%. The equipment segment experienced a slight decline of 3.6%. Total deferred revenue reached $35.4 million, up 12.7% year-over-year, providing revenue stability and financial visibility.
The company maintained a strong balance sheet with $25.3 million in cash as of March 31, 2025, which improved to approximately $30.5 million by May 9, 2025. Despite increased market uncertainties, management remains cautiously optimistic about 2025, citing historically stronger performance in later quarters.
Vaso (OTCQX: VASO) reported its Q4 and full-year 2024 financial results, achieving record annual revenue of $86.8 million, up 7% year-over-year. The company's Q4 2024 revenue increased 23.4% to $27.0 million, with growth across all business segments.
Key financial highlights for 2024:
- Gross profit increased 2.9% to $52.1 million
- Net income decreased to $1.0 million from $4.8 million in 2023
- Operating cash flow of $3.3 million
- Cash and equivalents of $26.3 million
- Deferred revenue grew 8% to $34.9 million
The decline in net income was primarily attributed to higher operating expenses, including investments in new programs and strategic activities. SG&A expenses increased 8.7% to $49.0 million, representing 56.5% of revenue.
Vaso (OTCQX: VASO) reported its Q4 and full-year 2024 financial results, achieving record annual revenue of $86.8 million, a 7% increase from 2023. Despite revenue growth, net income decreased to $1.3 million from $4.8 million in 2023 due to higher operating expenses.
Q4 2024 revenue increased 23.4% to $27.0 million, with growth across all segments: IT segment up 13.6% to $11.1 million, professional sales service up 31.2% to $15.0 million, and equipment segment up 31% to $921 thousand. The company maintained strong cash position with $26.3 million in cash and equivalents, while generating $3.3 million in operating cash flow during 2024.
Total deferred revenue grew 8% to $34.9 million, while adjusted EBITDA decreased to $1.4 million from $5.1 million in 2023. SG&A expenses increased 7.9% to $48.6 million, primarily due to higher personnel costs and expenses related to a terminated business combination transaction with Achari.
Vaso (OTCQX: VASO) announced key executive leadership changes effective January 1, 2025. Jane Moen, who has served as a Director since 2020, was appointed Chief Operating Officer while retaining her role as President of VasoHealthcare. Jonathan Newton was promoted to Chief Financial Officer from Co-Chief Financial Officer, with Michael Beecher transitioning to a financial and investor relations advisory role.
Additionally, Edgar Rios, who has served as an independent Director since 2011, was elected Vice Chairman of the Board of Directors and will continue as Chairman of the Board's Audit Committee. The company also appointed Kimberly Decker of Barley Snyder LLP as new corporate and securities outside counsel.
CEO Dr. Jun Ma emphasized these changes align with Vaso's human capital mission and 2025 strategy, focusing on organic growth across their diversified portfolio in human capital, MedTech, and information technology businesses.
Vaso (OTCQX: VASO), a company focused on human capital, information technology, and MedTech sectors, has released a shareholder and employee letter on December 16, 2024. The letter outlines the company's achievements throughout the year and presents strategic developments and priorities for 2025. The communication covers operational developments, product updates, financial performance, and thought-leadership initiatives, with details available on the company's website.
Vaso (OTCQX: VASO) reported Q3 2024 financial results with revenue of $20.8 million, up 7% from $19.4 million in Q3 2023, driven by growth in network services. However, the company recorded an operating loss of $1.4 million compared to operating income of $907,000 in Q3 2023. The company maintains a strong balance sheet with $26.8 million in cash and investments, and generated $3.6 million in operating cash flow during the first nine months. Deferred revenue increased by $1.4 million to $33.1 million. The net loss for Q3 2024 was $1.2 million, compared to net income of $1.2 million in Q3 2023, primarily due to business combination costs of $1.5 million.